Version 1
: Received: 5 December 2023 / Approved: 6 December 2023 / Online: 6 December 2023 (10:47:10 CET)
How to cite:
Martin, R. 100 Day Vaccine Development – An Alternative ApproachBoosters for Phase III Trialed Viral Family Vaccines. Preprints2023, 2023120408. https://doi.org/10.20944/preprints202312.0408.v1
Martin, R. 100 Day Vaccine Development – An Alternative ApproachBoosters for Phase III Trialed Viral Family Vaccines. Preprints 2023, 2023120408. https://doi.org/10.20944/preprints202312.0408.v1
Martin, R. 100 Day Vaccine Development – An Alternative ApproachBoosters for Phase III Trialed Viral Family Vaccines. Preprints2023, 2023120408. https://doi.org/10.20944/preprints202312.0408.v1
APA Style
Martin, R. (2023). 100 Day Vaccine Development – An Alternative ApproachBoosters for Phase III Trialed Viral Family Vaccines. Preprints. https://doi.org/10.20944/preprints202312.0408.v1
Chicago/Turabian Style
Martin, R. 2023 "100 Day Vaccine Development – An Alternative ApproachBoosters for Phase III Trialed Viral Family Vaccines" Preprints. https://doi.org/10.20944/preprints202312.0408.v1
Abstract
Researchers and organizations are pursing 100 Day Vaccine Development to reduce the impact of any new pandemic-causing virus. They propose monitoring viral emergence and developing vaccines for discovered viruses which would undergo safety testing in humans. If one of these viruses emerges, phase III trials would then take place. There are two problems with this approach- first, phase III trials are too long for the 100-day goal and second, the virus that emerged might not have been discovered in their surveillance. An alternative approach would be to first develop vaccines for viral families similar to the pan coronavirus vaccines being proposed for next generation COVID vaccines. Phase III trials for them would be run even if a virus in the family wasn’t having an outbreak. If a virus in a family for which a vaccine has been developed has an outbreak and the phase III trialed vaccine is not effective against it, develop a booster based on the phase III trialed vaccine. Since booster development and approval takes less than 100 days, the 100 Day Vaccine Development goal would be met.
Keywords
Vaccines 100 Day Vaccine Development COVID
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
